AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17720116
Drug: CT-controlled facet
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-controlled facet joint injections
Trial: 12087139
Drug: lopinavir-ritonavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir-ritonavir (400 mg of lopinavir plus 100 mg of ritonavir twice daily)
Trial: 12087139
Drug: nelfinavir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nelfinavir (750 mg three times daily)
Trial: 10215095
Drug: Complete forebrain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete forebrain commissurotomy (L.B.)
Trial: 30370532
Drug: Prolonged exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exercise training (12-week program: resistance exercise twice per week, high intensity interval training once per week)
Trial: 23871417
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m² every 21 days, intravenously) with Atrasentan (10 mg/day, orally)
Trial: 23871417
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m² every 21 days, intravenously) with Placebo
Trial: 21825080
Drug: 17.5 mg
RxNorm normalized name: acitretin 17.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 mg once-weekly risedronate
Trial: 21825080
Drug: Placebo (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (combined with daily 1000 IU of ergocalciferol)
Trial: 17080507
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg IR formulation)
Trial: 15809368
Drug: Intensive atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive atorvastatin to reduce LDL to <80 mg/dL (n=96)
Trial: 15809368
Drug: Intensive atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive atorvastatin to reduce LDL to <80 mg/dL plus antioxidant vitamins C (1000 mg/d) and E (800 mg/d) (n=101)
Trial: 15809368
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and low-dose lovastatin to reduce LDL to <130 mg/dL (n=103; control group)
Trial: 10211493
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with morphine (acupoint group)
Trial: 10211493
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with morphine (control group)
Trial: 7628595
Drug: ZDV (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZDV (500 mg daily) alone
Trial: 7628595
Drug: ZDV (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZDV (500 mg daily) with folinic acid (15 mg daily) and intramuscular vitamin B12 (1000 micrograms monthly)
Trial: 7628595
Drug: ZDV (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZDV (500 mg daily) with folinic acid and vitamin B12
Trial: 824172
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sublingual isosorbide dinitrate
Trial: 31576436
Drug: Levosimendan 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 0.2 µg/kg/min continuous infusion
Trial: 28177480
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy combined with bevacizumab (4 cycles of FEC followed by 4 cycles of docetaxel for HER2-negative tumours in BEVERLY-1; docetaxel and trastuzumab for HER2-positive tumours in BEVERLY-2)
Trial: 28177480
Drug: CTC detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC detection at baseline (≥1 CTC/7.5 ml)
Trial: 28177480
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pCR after neoadjuvant treatment with no CTC detection at baseline
Trial: 28177480
Drug: CEC level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEC level at baseline or variations during treatment
Trial: 19401663
Drug: VAP technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAP technique (4 applications of 2 ml lidocaine 2% with oxygen flow of 3 l min(‐1))
Trial: 19401663
Drug: STAN technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAN technique (insufflation of 3 l min(‐1) oxygen via nasal probe and two applications of 4 ml of lidocaine 2%)
Trial: 10379018
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 microg, twice daily)
Trial: 2202199
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA) suppositories, 400 mg bid
Trial: 27377616
Drug: Lidocaine/tetracaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/tetracaine cream
Trial: 25251749
Drug: Group phone
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group phone participation (CC)
Trial: 19322907
Drug: Biologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic therapy (antitumor necrosis factor agents) for patients at highest risk of recurrence
Trial: 8006284
Drug: Captopril (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75 mg daily)
Trial: 23758456
Drug: Visible-light curing
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visible-light curing of pulp capping compounds (Groups 1-7)
Trial: 23758456
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser irradiation without prior application of a pulp capping compound (Groups 8-10)
Trial: 19285304
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion for the first 24 hours after surgery
Trial: 11518073
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort (Ze 117; 500 mg extract/day)
Trial: 9457399
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous rIL-2 alone
Trial: 9457399
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous rIL-2 plus rIFN-alpha
Trial: 9457399
Drug: Moderate-dose outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose outpatient subcutaneous rIL-2 plus rIFN-alpha
Trial: 2905387
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage chlorthalidone
Trial: 27479536
Drug: Next-step treatment
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next-step treatment for MDD after failing initial antidepressant trial
Trial: 27479536
Drug: Next-step treatment
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next-step treatment for MDD
Trial: 25799445
Drug: Rapid palatal
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid palatal expansion (RPE) and facial mask (FM) therapy
Trial: 21083927
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing (warfarin therapy based on algorithms using clinical information and genotypes for polymorphisms in CYP2C9 and VKORC1)
Trial: 21083927
Drug: Clinical-guided dosing
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical-guided dosing (warfarin therapy based on algorithms using only clinical information)
Trial: 16369994
Drug: Tamoxifen or
RxNorm normalized name: tamoxifen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen or toremifene alone or in combination with chemotherapy (either concurrently or sequentially)
Trial: 16369994
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy alone (tamoxifen or toremifene)
Trial: 16369994
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy or beyond 3 months after completing chemotherapy
Trial: 1512327
Drug: Heparin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin therapy (5,000 U bolus followed by 1,000 U/h continuous infusion)
Trial: 1512327
Drug: Heparin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin therapy (optimal anticoagulation)
Trial: 1512327
Drug: Heparin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin therapy (suboptimal anticoagulation)
Trial: 1512327
Drug: Heparin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin therapy (inadequate anticoagulation)
Trial: 6527973
Drug: 2.5mg intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg intravenous nicardipine
Trial: 6527973
Drug: 10mg intravenous
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg intravenous nicardipine
Trial: 30442501
Drug: dinutuximab beta
RxNorm normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dinutuximab beta with subcutaneous IL-2
Trial: 25180702
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise program (15-20 minutes, up to 6 times weekly for 12 months)
Trial: 22160145
Drug: Darunavir/ritonavir triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir triple therapy
Trial: 20813583
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (maximum 3mg/24h)
Trial: 17430326
Drug: Granisetron-dexamethasone combination
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron-dexamethasone combination (granisetron 40 microg/kg and dexamethasone 150 microg/kg)
Trial: 15478386
Drug: Active cough
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active cough treatment
Trial: 9506736
Drug: Suppressive doses
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive doses of L‐T4
Trial: 30704923
Drug: Eltrombopag 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 200 mg (100 mg for east Asians) once daily during induction chemotherapy
Trial: 28641384
Drug: Lupron® injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupron® injections (7.5 mg)
Trial: 28641384
Drug: Lupron and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupron and testosterone (L+T) replacement for 49 days
Trial: 24403557
Drug: JS7 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS7 DNA vaccine and MVA/HIV62B (DDMM regimen)
Trial: 22275160
Drug: Fasudil 40
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil 40 mg
Trial: 22275160
Drug: Fasudil 80
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil 80 mg
Trial: 22275160
Drug: Fasudil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasudil (40 mg or 80 mg)
Trial: 7602350
Drug: Ifosfamide 5
RxNorm normalized name: ifosfamide 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 5 g/m2 by 24-hour continuous intravenous infusion with mesna on day 1, carboplatin 300 mg/m2 intravenously on day 1, etoposide 50 mg/m2 orally on days 1 to 21 every 4 weeks (schedule I)
Trial: 7602350
Drug: Ifosfamide 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 3.75 g/m2 IV on day 1, carboplatin 300 mg/m2 IV on day 1, etoposide 50 mg orally on days 1 to 14 (schedule II)
Trial: 7602350
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (ICE regimen)
Trial: 2085990
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol (3 grams, single dose)
Trial: 2085990
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg b.i.d. for 7 days)
Trial: 282070
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg, orally)
Trial: 282070
Drug: Nifedipine (sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (sublingual route)
Trial: 31207253
Drug: High soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High soy protein (HSP; 50 g)
Trial: 31207253
Drug: Low soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low soy protein (LSP; 25 g)
Trial: 31207253
Drug: Control (CON;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (CON; 50 g carbohydrate)
Trial: 25991760
Drug: Standard major
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard major haemorrhage therapy (STANDARD)
Trial: 22664119
Drug: Deferiprone 75
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone 75 mg/kg/day TDS orally with deferoxamine 30-50 mg/kg subcutaneously every other day
Trial: 22664119
Drug: Deferoxamine 30-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine 30-50 mg/kg/day subcutaneously for 6-12 hours/day and 5-6 days per week
Trial: 17524772
Drug: Straight scleral
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Straight scleral injection
Trial: 15374722
Drug: Endometrial laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial laser intrauterine thermal therapy (ELITT)
Trial: 9539615
Drug: Acetyl starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl starch (ACS) 6% i.v. at 15 mL/kg up to 1000 mL
Trial: 9539615
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch (HES) 6% i.v. at 15 mL/kg up to 1000 mL
Trial: 21411655
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg naloxone
Trial: 7855219
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg naloxone
Trial: 30671872
Drug: Two-hourly repositioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-hourly repositioning 24/7
Trial: 28815282
Drug: 20 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg/day calcidiol
Trial: 28815282
Drug: 40 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg/day calcidiol
Trial: 28815282
Drug: 125 μg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 μg/week calcidiol
Trial: 11254020
Drug: Inositol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inositol (12 g)
Trial: 8350363
Drug: Tamoxifen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (40 mg daily for 2 or 5 years)
Trial: 31282542
Drug: Dipyridamole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (100 mg 4 times a day)
Trial: 31322200
Drug: Spirulina, curcumin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina, curcumin, and Boswellia supplement
Trial: 28425818
Drug: 3-dose priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-dose priming and booster (3 + 1)
Trial: 28425818
Drug: 2-dose priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-dose priming and booster (2 + 1)
Trial: 28425818
Drug: 3-dose priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-dose priming without booster (3 + 0)
Trial: 12617375
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (sham short-wave therapy for 30 minutes) combined with conventional physiotherapy
Trial: 27048747
Drug: Control (current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (current combination antiretroviral therapy)
Trial: 25149882
Drug: INSURE method
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INSURE method (Intubation, Surfactant administration and extubation)
Trial: 22078337
Drug: Trigone-including injections
RxNorm normalized name: Trigonella foenum-graecum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigone-including injections of 500 U abobotulinumtoxinA diluted to 20ml
Trial: 22078337
Drug: Trigone-sparing injections
RxNorm normalized name: Trigonella foenum-graecum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigone-sparing injections of 500 U abobotulinumtoxinA diluted to 20ml
Trial: 22078337
Drug: Trigone-including injections
RxNorm normalized name: Trigonella foenum-graecum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigone-including injections
Trial: 22078337
Drug: Trigone-including and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigone-including and trigone-sparing injections
Trial: 7627386
Drug: Ranitidine, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 100 mg IV twice a day for two days, followed by 150 mg orally twice a day for three days
Trial: 28536723
Drug: Two-way SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-way SMS medication reminders
Trial: 26384233
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of alcohol intake (0.4 g/kg)
Trial: 20137473
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg recombination yeast hepatitis B vaccine (3 doses at 0 month, 1st month, 6th month)
Trial: 18297891
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (usually in combination with folic acid)
Trial: 18297891
Drug: Withholding iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding iron supplementation until treatment schedule is complete
Trial: 11476462
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg q.d.
Trial: 11476462
Drug: Oxatomide 25
RxNorm normalized name: oxatomide 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide 25 mg q.d.
Trial: 9170765
Drug: TP (treatment-plan-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP (treatment-plan-related tasks)
Trial: 9170765
Drug: UA (urine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UA (urine samples testing negative for illicit drugs)
Trial: 9170765
Drug: STD (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STD (standard treatment)
Trial: 23063633
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg daily of saw palmetto extract
Trial: 23063633
Drug: 640 mg
RxNorm normalized name: glycerin 1640 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 640 mg daily of saw palmetto extract
Trial: 23063633
Drug: 960 mg
RxNorm normalized name: glycerin 960 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 mg daily of saw palmetto extract
Trial: 18065796
Drug: Acetate-Free Biofiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate-Free Biofiltration with constant potassium (2.5 mEq/l) (AFB)
Trial: 12972523
Drug: Gemcitabine 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,250 mg/m2 IV on days 1 and 8, and cisplatin 100 mg/m2 IV on day 1 (GC arm)
Trial: 12972523
Drug: Irinotecan 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 150 mg/m2 IV on day 1 and cisplatin 80 mg/m2 IV on day 1 (IC arm)
Trial: 10358993
Drug: Specific therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific therapy and ultrasonic treatment (44 KHz, amplitude 2 microm to the paravertebral region and PT zones)
Trial: 10358993
Drug: Specific therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific therapy only
Trial: 8665055
Drug: rhDNase 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNase 2.5 mg in 2.5 ml excipient twice a day (n = 43)
Trial: 8665055
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml excipient alone twice daily (n = 37)
Trial: 8665055
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (rhDNase and control)
Trial: 1874198
Drug: Frusemide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 0.5 mg kg‐1 at the onset of hypotension (Group F)
Trial: 6352599
Drug: Azlocillin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azlocillin (18 g/day, intravenously)
Trial: 6352599
Drug: Gentamicin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (3 to 5 mg/kg/day, intramuscularly)